drugset / Trial / NCT00126685

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00126685

Non-randomizedOpen-labelTreatment

Summary

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IV melanoma.

Timeline

Start
2005-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous tumor cell vaccine Vaccine Intravenous
Subject therapeutic autologous dendritic cells Vaccine Intravenous

Indications